Table 1 Mutation status in RAS and methylation status and clinical characteristics
Characteristics | Mutation in RAS (n = 22) | No mutation in RAS (n = 100) | p value |
|---|---|---|---|
Median age (range) | 54 (29.1–81.7) | 62 (23.4–86.1) | 0.14 |
Sex | 0.48 | ||
Male (%) | 15 (68%) | 59 (59%) | |
Female (%) | 7 (32%) | 41 (41%) | |
Cytogenetic risk | 1 | ||
Poor (%) | 9 (41%) | 42 (42%) | |
Intermediate (%) | 10 (45%) | 50 (50%) | |
Unevaluable (%) | 3 (14%) | 8 (8%) | |
PB blasts at screening (%), median (range) | 58 (0–99) | 5.5 (0–93) | < 0.0001 |
BM blasts at screening (%), median (range) | 49 (18–95) | 31.1 (2–94) | 0.0005 |
Platelet count (K/μL) at screening, median (range) | 31.5 (7–230) | 36 (2–342) | 0.44 |
Hemoglobin (g/dL) at screening, median (range) | 9.4 (7.2–12.6) | 9.3 (6.0–14.4) | 0.96 |
WBC (K/μL) at screening, median (range) | 9.5 (1.5–36.2) | 2.1 (0.2–75.5) | 0.0007 |
LINE-1 maximum demethylation %, mean ± SE* | 18.9 ± 3.2 | 24.3 ± 1.3 | 0.056 |
IDH mutation | 5 (23%) | 18 (18%) | 0.56 |
Methylation cluster | 0.0009 | ||
CIMP-like | 10 (45%) | 31 (31%) | |
Intermediate | 11 (50%) | 24 (24%) | |
Normal-like | 0 | 40 (40%) | |
Unknown | 1 (5%) | 5 (5%) | |
Response | |||
Complete CR rate (%) | 0 | 15/100 (15%) | 0.07 |
CRc rate (%) | 3/22 (14%) | 23/100 (23%) | 0.4 |
Median survival days (range) | 129.5 (12–783+) | 233 (7–1088+) | 0.0004 |
2-year survival rate | 1/22 (5%) | 19/100 (19%) | 0.12 |